4D Molecular Therapeutics Inc.

$FDMT as up over 100% earlier after releasing data from its phase 2 PRISM clinical trial for 4D-150.

Share this article:

About the Author:

4D Molecular Therapeutics Inc.

Joey Ramson

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup